Intra-articular glucocorticoid (IAGC) injection is associated with rapid clinical resolution and reduced need for additional treatment, making it an effective and safe second-line strategy for persistent Lyme arthritis in children, a recent study has shown.
Fibromyalgia patients with comorbid insomnia more often receive prescription medications for fibromyalgia and use ambulatory care services relative to their counterparts without the sleep disorder, according to a study, suggesting that comorbidity with insomnia substantially increases its burden.
Interleukin-1 inhibition with lutikizumab does not yield substantial analgesic or anti-inflammatory effects in the treatment of patients with knee osteoarthritis (OA) and associated synovitis, with the results of a phase II trial showing limited improvement in pain and synovitis.
Dual neutralization with interleukin (IL)-7A and IL-17F with bimekizumab produces rapid reductions in disease activity in rheumatoid arthritis (RA) patients with inadequate response to certolizumab pegol, as shown in the results of a phase IIa, proof-of-concept study.
A treat-to-target strategy using first-line monotherapy with recombinant interleukin‐1 receptor antagonist (rIL‐1Ra; anakinra) appears to be highly effective in systemic juvenile idiopathic arthritis (JIA), resulting in early and sustained inactive disease, reduced glucocorticoid use, and lower incidence of long‐term disease‐ and therapy‐related damage, according to the results of a study.
The burden of carotid atherosclerosis, as detected and quantified by ultrasound, in patients with psoriatic disease (PsD) independently predicts future incident cardiovascular (CV) events, according to a recent study. Hence, combining this vascular imaging data with clinical and laboratory measures of traditional CV risk factors could improve the accuracy of CV risk stratification in PsD.
Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.